---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-050236"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T07:44:10.276442+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Renalytix reports FY2023 results: FDA authorization, 55% test growth, $11M cost cuts

## Summary
- FDA De Novo marketing authorization for KidneyIntelX.dkd to assess kidney decline risk in diabetic patients.
- Over 5,000 KidneyIntelX tests performed in FY2023, up 55% from prior year.
- Reduced annual operating expenses by over $11M vs prior year; additional cuts underway.
- Completed $20.3M equity financing in February 2023 led by new institutional investors.
- Secured multiple insurance contracts including EmblemHealth and CareFirst; over 40 commercial payors.

## SEC filing metadata
- accession: 0000950170-23-050236
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017023050236/0000950170-23-050236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017023050236/rnlx-20230928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-050236
- JSON: https://secwatch.observer/filing/0000950170-23-050236.json
- Plain text: https://secwatch.observer/filing/0000950170-23-050236.txt

## Key facts
- Earnings Releases
  Renalytix plc reported financial results for the fiscal year ended June 30, 2023.
  - Period: the fiscal year ended June 30, 2023
  - Result: reported results
  source text: Renalytix plc (the “Company”) issued a press release announcing its financial results for the quarter and year ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023050236/0000950170-23-050236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.